Clinical Trials Logo

Filter by:
NCT ID: NCT03901339 Completed - Clinical trials for Metastatic Breast Cancer

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

TROPiCS-02
Start date: May 8, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).

NCT ID: NCT03901287 Completed - Clinical trials for Pulmonary Hypertension

Quantitative Dual Energy Computed Tomography in Pulmonary Hypertension

DECTPH
Start date: August 2, 2019
Phase: N/A
Study type: Interventional

Pathophysiological mechanisms leading to pulmonary hypertension (PH) are complex. Quantitative computed tomography (QCT) can help us to study morphological alterations in patients with PH. These CT morphometrics are useful to predict the degree of PH severity at least in PH secondary to chronic obstructive pulmonary disease (COPD). We hypothesized that assessing lung perfusion using dual energy CT (DECT) can refine our knowledge on PH pathophysiology and help to predict PH severity irrespective of its etiology

NCT ID: NCT03900819 Completed - Peritoneal Dialysis Clinical Trials

Evaluation of Dexterity in Prevalent Peritoneal Dialysis Patients

DEXTER
Start date: January 1, 2019
Phase:
Study type: Observational

The objective of the study is to measure the manual dexterity of patients treated by peritoneal dialysis - transversal study

NCT ID: NCT03899922 Completed - Uveitis Clinical Trials

Monitoring Drug-induced Uveitis

UVETOX
Start date: April 1, 2019
Phase:
Study type: Observational

Several drugs and chemotherapies seem to induce uveitis. This study investigates reports of uveitis, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

NCT ID: NCT03899896 Completed - Gender Dysphoria Clinical Trials

Voice Feminisation in Transgender Women

FemVoc
Start date: February 28, 2019
Phase:
Study type: Observational

The voice is a reflection of our identity. In the case of transgender women, there may be a gap between perceived male voice and female appearance. Indeed, hormonal treatment in transgender women has no effect on the voice quality. This gap can have negative consequences on everyday life in banal situations such as telephonic contact leading to limited use of phone calls and social isolation. Differences between female and male voices seem to be socially determined and do not depend directly on sexual dimorphism of the phonatory organs. Speech therapy might thus be indicated as a vocal support for transgender women. Only few studies have examined the impact of perceived voice on the quality of life of transgender women.

NCT ID: NCT03898791 Completed - Clinical trials for Small Cell Lung Cancer

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Start date: July 16, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

NCT ID: NCT03898544 Completed - Clinical trials for Knee Arthroplasty, Total

Gait Kinematics After Primary Total Knee Arthroplasty (TKA) Versus Revision TKA

Stryker-KneeKG
Start date: March 18, 2019
Phase:
Study type: Observational

The functional outcomes after TKA are satisfying with a full recovery at 6 months - 1 year. Nevertheless, the revisions of TKA have often lower functional results than primary TKA with a long delay of recovery. The Stryker TKA present the same device for primary TKA and for revision. The aim of this study is to compare the gait kinematics at 6 months after primary Stryker TKA or Revision Stryker TKA to assess if the objective outcomes are similar with this device.

NCT ID: NCT03898453 Completed - Clinical trials for Breast Cancer Female

EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient

PSYCANCER
Start date: March 11, 2019
Phase: N/A
Study type: Interventional

The study will consist in an evaluation of the EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the context on invasive primitive breast cancer. EMDR could then allow the affected patients to readjust their point of view on the pathology and thus promote more adapted behaviors or additional resources to cope with the disease. 190 Patients are going to be randomized in two groups : one group with EMDR psychotherapists and one group with support psychotherapists. Patients will receive 8 sessions. We expect that patient in EMDR psychotherapists group will have an higher decrease of anxiety score, depressive score (CES-D) and PTSD score, and a higher increase in quality of life.

NCT ID: NCT03898440 Completed - Prenatal Disorder Clinical Trials

Fetal Ano-genital Distance in 2D Ultrasound.

DAG
Start date: April 15, 2019
Phase:
Study type: Observational

The purpose of this study is to determine a threshold value of fetal anogenital distance in 2D ultrasound to differentiate male fetuses from female fetuses, starting 18 weeks of gestation and until the due date. The study also evaluates the feasibility of the measure and its interobserver variability.

NCT ID: NCT03898284 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis

OSCILLO
Start date: April 23, 2019
Phase:
Study type: Observational

A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis. There is a need for techniques allowing to characterize disease progression earlier, so that treatment may be adapted as early as possible in the lack of a response. Hypothesis. Our hypothesis is that 3-month changes of lung function parameters measured by a novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in idiopathic pulmonary fibrosis.